文献速递眼底病与葡萄膜炎

雷珠单抗治疗伴与不伴息肉状脉络膜血管病变患者的真实世界有效性与安全性:LUMINOUS 研究 12 个月结果

REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study.
PubMed 文献 · Retina · 2020-01-01

LUMINOUS 研究评估雷珠单抗 0.5 mg 治疗初治伴或不伴息肉状脉络膜血管病变(PCV)的新生血管性年龄相关性黄斑变性患者 12 个月的真实世界有效性与安全性。第 12 个月时 PCV 组与非 PCV 组平均视力分别较基线提高 +5.0 与 +3.0 个字母,平均注射次数分别为 4.4 与 5.1 次,严重眼部不良事件发生率分别为 0.7% 与 0.9%。LUMINOUS 研究证实雷珠单抗在初治 PCV 患者中的有效性与安全性。

要点

  • 第 12 个月 PCV 组平均视力较基线提高 +5.0 个字母,非 PCV 组提高 +3.0 个字母。
  • PCV 组平均注射 4.4 次,非 PCV 组平均注射 5.1 次。
  • 严重眼部不良事件发生率 PCV 组 0.7%,非 PCV 组 0.9%。

核心结论

  • LUMINOUS 研究证实雷珠单抗在初治 PCV 患者中的有效性与安全性。

研究设计与样本

  • LUMINOUS 研究中对伴或不伴 PCV 的新生血管性年龄相关性黄斑变性患者接受雷珠单抗治疗 12 个月后的评估。
  • 基线时伴 PCV 患者 572 例,不伴 PCV 患者 5,644 例。

主要发现

  • 第 12 个月 PCV 组与非 PCV 组平均视力较基线分别提高 +5.0 与 +3.0 个字母,平均注射次数分别为 4.4 与 5.1 次。
  • 基线视力 ≥73 个字母的 PCV 患者中 80% 与非 PCV 患者中 72.2% 在第 12 个月维持该视力水平。
  • 基线视力 <73 个字母的患者中,PCV 组 20.6% 与非 PCV 组 17.9% 在第 12 个月达到视力 ≥73 个字母。
  • PCV 组较非 PCV 组观察到更大幅度的中央视网膜厚度较基线降低。
  • 严重眼部不良事件发生率 PCV 组为 0.7%,非 PCV 组为 0.9%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the real-world effectiveness and safety of intravitreal ranibizumab 0.5 mg in treatment-naive patients with and without polypoidal choroidal vasculopathy (PCV). METHODS: Assessment of neovascular age-related macular degeneration patients with or without PCV after 12 months of ranibizumab treatment during the LUMINOUS study. Outcome measures were visual acuity and central retinal thickness changes from baseline and the rate of ocular adverse events. RESULTS: At baseline, 572 and 5,644 patients were diagnosed with and without PCV, respectively. The mean visual acuity gain from baseline at Month 12 in the PCV and non-PCV groups was +5.0 and +3.0 letters, respectively; these gains were achieved with a mean of 4.4 and 5.1 ranibizumab injections. Eighty percent of PCV patients and 72.2% of non-PCV patients who had baseline visual acuity ≥73 letters maintained this level of vision at Month 12; 20.6% and 17.9% of patients with baseline visual acuity <73 letters achieved visual acuity ≥73 letters in these groups. Greater reductions in central retinal thickness from baseline were also observed for the PCV group versus the non-PCV group. The rate of serious ocular adverse events was 0.7% (PCV group) and 0.9% (non-PCV group). CONCLUSION: LUMINOUS confirms the effectiveness and safety of ranibizumab in treatment-naive patients with PCV.

来源:Retina,查看原文。版权归原作者所有。

引用

  1. Koh A, Lai TYY, Wei WB, et al. REAL-WORLD EFFECTIVENESS AND SAFETY OF RANIBIZUMAB TREATMENT IN PATIENTS WITH AND WITHOUT POLYPOIDAL CHOROIDAL VASCULOPATHY: Twelve-Month Results From the LUMINOUS Study. Retina. 2020. PMID: 31385918. doi:10.1097/IAE.0000000000002624

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。